Tuberculosis Epidemiology Forecast 2026-2035

Tuberculosis (TB) is a chronic infectious disease caused by Mycobacterium tuberculosis, primarily affecting the lungs and transmitted through airborne droplets. According to the World Health Organization (WHO), an estimated 10.7 million people developed tuberculosis in 2024, corresponding to 131 cases per 100,000 population, with 5.8% co-infected with HIV. As per the tuberculosis epidemiology forecast, the disease burden continues to necessitate strengthened surveillance and control strategies worldwide.

Tuberculosis Epidemiology Forecast Report Coverage

The analyst's “Tuberculosis Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of tuberculosis. It projects the future incidence and prevalence rates of tuberculosis cases across various populations. The study covers age, gender, and type as major determinants of the Tuberculosis population. The report highlights patterns in the prevalence of tuberculosis over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of tuberculosis in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Tuberculosis Understanding: Disease Overview

Tuberculosis (TB) is a contagious infectious disease caused by the bacterium Mycobacterium tuberculosis, primarily affecting the lungs but capable of involving other organs such as the kidneys, spine, and brain. It spreads through airborne droplets when an infected individual coughs or sneezes. TB is broadly classified into latent tuberculosis infection, where the bacteria remain inactive without symptoms, and active tuberculosis disease, which presents with clinical symptoms and is transmissible. Pulmonary tuberculosis is the most common form, while extrapulmonary tuberculosis affects other body sites. Risk factors include weakened immunity, malnutrition, and close contact with infected individuals.

Tuberculosis Epidemiology Perspective

The tuberculosis epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The analyst provides both current and predicted trends for the tuberculosis epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for Tuberculosis and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to the World Health Organization (WHO), tuberculosis cases are most concentrated in adults aged 25-54 years globally, while the Western Pacific Region shows higher burden in ≥65 years due to population ageing and reactivation risk, particularly influenced by trends in China.
• As per the World Health Organization, in 2024, 54% of tuberculosis cases occurred in men, 35% in women, and 11% in children. Men account for 66-75% of adult cases, reflecting higher exposure, delayed diagnosis, and greater transmission impact.
• According to the Centers for Disease Control and Prevention, tuberculosis remains the 13th leading cause of death globally, with 10.6 million cases and 1.6 million deaths reported in 2021, highlighting its continued burden as a major infectious killer worldwide.
• As per the Centers for Disease Control and Prevention, nearly one-quarter of the global population is latently infected, with a 5-10% lifetime risk of developing active tuberculosis, indicating a substantial reservoir contributing to ongoing incidence, especially in high-burden regions.
• According to Fengwen Huang et al., 2024, tuberculosis prevalence in China shows higher susceptibility among adults aged 20-50 years and older populations, while individuals below 20 years exhibit lower infection rates, with regional clustering in northwestern and southwestern areas.

Country-wise Tuberculosis Epidemiology

The tuberculosis epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Across the covered regions, tuberculosis epidemiology shows marked geographic variation, with higher burden persisting in Asia compared to Western countries. In India, incidence declined from 237 to 187 per lakh population between 2015 and 2024, with 26.18 lakh notified cases and mortality reduced to 21 per lakh, as per the World Health Organization and Ministry of Health and Family Welfare. In the United States, cases remain concentrated among non-United States-born populations, accounting for 87% in Virginia, according to the Virginia Department of Health. Japan reported 10,096 cases in 2023 with a notification rate of 8.1 per 100,000, as per the Research Institute of Tuberculosis.

Tuberculosis: Treatment Overview

The treatment of tuberculosis involves a standardized, multi-drug antibiotic regimen administered over a prolonged period, typically six to nine months. First-line anti-tubercular drugs include isoniazid, rifampicin, pyrazinamide, and ethambutol, used in combination to prevent drug resistance. Treatment is divided into an intensive phase and a continuation phase to ensure complete eradication of the bacteria. Directly observed treatment, short-course (DOTS), recommended by the World Health Organization, enhances adherence and treatment success. In cases of drug-resistant tuberculosis, second-line medications and longer treatment durations are required, often with closer clinical monitoring.

Key Questions Answered

• What are the key findings of tuberculosis epidemiology in the 8 major markets?
• What will be the total number of patients with tuberculosis across the 8 major markets during the forecast period?
• What was the country-wise tuberculosis epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of tuberculosis patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of tuberculosis during the forecast period of 2026-2035?
• What are the currently available treatments for tuberculosis?
• What are the disease risks, signs, symptoms, and unmet needs of tuberculosis?

Scope of the Tuberculosis Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of tuberculosis based on several factors.
• Tuberculosis Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The tuberculosis report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.